LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Cerrado

SectorSanidad

10.2 2.41

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.86

Máximo

10.32

Métricas clave
By Trading Economics
Ingresos	7.7M -73M
Ventas	929K 18M
BPA	-0.828
Margen de beneficios	-401.495
Empleados	260
EBITDA	7.4M -78M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+181.95% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	159M 1B
Apertura anterior	7.79
Cierre anterior	10.2

Noticias sobre sentimiento de mercado

By Acuity

50%

161 / 344 Clasificación en Healthcare

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 may 2026, 23:08 UTC

Adquisiciones, fusiones, absorciones

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 may 2026, 20:53 UTC

Ganancias

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 may 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 20:33 UTC

Charlas de Mercado

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 may 2026, 20:11 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 19:47 UTC

Ganancias

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 may 2026, 19:36 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

29 may 2026, 19:34 UTC

Charlas de Mercado

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 may 2026, 19:22 UTC

Charlas de Mercado

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 may 2026, 19:05 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 may 2026, 18:19 UTC

Charlas de Mercado

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 may 2026, 18:12 UTC

Adquisiciones, fusiones, absorciones

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 may 2026, 18:11 UTC

Charlas de Mercado

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 may 2026, 18:10 UTC

Charlas de Mercado

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 may 2026, 17:55 UTC

Ganancias

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 may 2026, 17:55 UTC

Charlas de Mercado

NEAR Protocol Nearly Doubles in May -- Market Talk

29 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 may 2026, 17:00 UTC

Ganancias

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

29 may 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

29 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

29 may 2026, 16:02 UTC

Charlas de Mercado

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 may 2026, 15:55 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

29 may 2026, 15:55 UTC

Charlas de Mercado

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 may 2026, 15:50 UTC

Adquisiciones, fusiones, absorciones

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 may 2026, 15:50 UTC

Adquisiciones, fusiones, absorciones

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 may 2026, 15:40 UTC

Charlas de Mercado

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 may 2026, 15:20 UTC

Charlas de Mercado

Canada's Economy Not Looking All That Bright -- Market Talk

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

181.95% repunte

Estimación a 12 Meses

Media 28.11 USD 181.95%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

161 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.